Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement

Assessment Status Full HTA Assessment
HTA ID -
Drug Rivaroxaban
Brand Xarelto®
Indication For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.
Assessment Process
Full submission received from Applicant 01/05/2008
NCPE assessment completed 18/09/2008
NCPE assessment outcome Reimbursement Recommended

A summary of the main findings are included in the attached document.

Technical Summary